ProQR Therapeutics (NASDAQ:PRQR) Raised to “Hold” at Wall Street Zen

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

PRQR has been the topic of several other research reports. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Chardan Capital cut their target price on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Finally, JonesTrading lowered their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.33.

ProQR Therapeutics Price Performance

PRQR stock opened at $1.92 on Friday. ProQR Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.10. The company has a market cap of $202.29 million, a price-to-earnings ratio of -4.17 and a beta of 0.07. The business has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $1.66.

Insider Activity at ProQR Therapeutics

In other ProQR Therapeutics news, Director Bart Filius acquired 150,000 shares of the company’s stock in a transaction on Friday, July 17th. The shares were acquired at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the acquisition, the director directly owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Boer Daniel Anton De purchased 150,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were acquired at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares in the company, valued at $522,000. This represents a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 600,000 shares of company stock valued at $988,500. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. increased its stake in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the last quarter. Guggenheim Capital LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth about $35,000. Invesco Ltd. purchased a new position in ProQR Therapeutics during the 4th quarter valued at about $51,000. Axiom Investment Management LLC purchased a new position in ProQR Therapeutics during the 1st quarter valued at about $53,000. Finally, Simplex Trading LLC raised its position in ProQR Therapeutics by 44,169.0% during the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 44,169 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.